Necroptosis, tumor necrosis and tumorigenesis

Zheng-gang Liu1,* and Delong Jiao1

1 Laboratory of Immune Cell Biology, Center for Cancer Research, National Cancer Institute; National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892.

* Corresponding Author:
Zheng-gang Liu, Laboratory of Immune Cell Biology, Center for Cancer Research, NCI, NIH, Bldg 37, Rm 1130, 37 Convent Dr., Bethesda, MD 20892, USA; Tel: 240-760-6826; E-mail: zgliu@box-z.nih.gov

ABSTRACT Necroptosis, known as programmed necrosis, is a form of caspase-independent, finely regulated cell death with necrotic morphology. Tumor necrosis, foci of necrotic cell death, occurs in advanced solid tumors and is often associated with poor prognosis of cancer patients. While it is well documented that apoptosis plays a pivotal role to tumor development, the role of necroptosis in tumorigenesis is still not fully understood as recent studies have reported both tumor-promoting and tumor-suppressing effects of necroptosis. In this short review, we will discuss some recent studies about the role of necroptosis in tumorigenesis and speculate the implications of these findings in future research and potential novel cancer therapy targeting necroptosis.

INTRODUCTION Cell death can happen through either an active, regulated process, known as programmed cell death, or a passive, uncontrolled course. Because of the dramatic morphological differences of these two types of cell death, they were originally coined as apoptosis and necrosis, respectively [1-4]. Apoptosis is defined as programmed cell death characterized by the activation of caspases, which are cysteine proteases that cleave cellular substrates, and the morphological features of cellular shrinkage, chromatin condensation, nuclear fragmentation, and membrane blebbing [1, 4]. At the end of the apoptotic process, dying cells are broken to membrane-bounded bodies containing the cellular structures and organelles, known as apoptotic bodies, which are taken up by surrounding cells or by phagocytic cells of the immune system without triggering inflammation [3, 4]. In contrast, necrosis is thought to be independent of the activity of caspases and is characterized by cellular swelling, organelle dysfunction, extensive mitochondrial damage, and plasma membrane rupture [2-4]. Because necrotic cells release their cell contents including proteins and nucleic acids, necrosis is much more inflammatory compared to apoptosis [2, 3].

In recent years, the concept of cell death has evolved dramatically because of the extensive studies of the role of cell death in normal tissue homeostasis and in the wide spectrum of diseases including autoimmune disease, neurodegenerative diseases and cancer [5, 6]. It is now accepted that there are other forms of programmed cell death such as pyroptosis and ferroptosis that are distinct...
from apoptosis [5, 6]. While engaging pyroptosis needs the activation of Caspase-1, pyroptotic cell death leads to the rupture of plasma membrane and the release of cell contents, which results in the subsequent inflammatory responses [5, 6]. Ferroptosis is a nonapoptotic, iron-dependent form of cell death [5, 6]. More importantly, it has been found that necrosis could also happen in a programmed, finely regulated fashion under certain conditions. For instance, when apoptosis is blocked, tumor necrosis factor (TNF) triggers certain types of cells to undergo a regulated necrotic cell death. This regulated necrosis is termed as necroptosis [5-9].

Apoptosis inhibits tumor progression and a hallmark of cancer is the ability of cancer cells to evade apoptosis [10]. Studies suggest that ferroptosis may play a similar role in tumorigenesis as apoptosis does [11]. While the important role of necroptosis in chemotherapy drug-induced cell death of cancer cells has been established, the role of necroptosis in tumorigenesis is still elusive. Here, we will go over some recent findings on the involvement of necroptosis in tumorigenesis and discuss the insights provided by these studies about the role(s) of necroptosis in tumor progression and the potential of novel cancer therapy targeting necroptosis.

**NECROPTOSIS: A TYPE OF PROGRAMMED NECROSIs**

Necroptosis is a form of programmed, caspase-independent necrosis and has all of the morphological features of necrosis [5-9]. Necroptosis has originally been observed by studying death receptor-induced cell death [12], but it is clear now that necroptosis mostly happens under pathological conditions in vivo, such as viral infection [6-9]. Many aspects of the molecular mechanism of necroptosis were revealed through studying death receptor-induced necroptosis [6-9]. For death-receptor-induced necroptosis, the protein kinase receptor interacting protein kinase 1, 3 (RIPK1, RIPK3) and the mixed lineage kinase domain-like (MLKL) constitute the core of the necroptosis machinery (Figure 1) [6-9]. As a death domain containing kinase, RIPK1 plays a key role in multiple pathways of death receptor signaling, such as the activation of NF-kB and MAP (mitogen-activated protein) kinases, and the induction of apoptosis and necroptosis [6-9, 13, 14]. Following the engagement of death receptors, RIPK1 is recruited to the death receptor signaling complexes through death domain interactions to mediate NF-kB and MAP kinase activation [13, 14]. Under certain conditions, these death receptor complexes could convert to the cytosolic, RIPK1-orchestrated signaling complexes to mediate cell death. For instance, in the case of TNFRII signaling, when the ubiquitination by cIAP (cellular inhibitor of apoptosis protein) proteins is inhibited, a RIPK1-centered cytosolic complex, known as complex Ia, is formed through recruiting FADD (Fas-associated death domain) and Caspase 8 (Casp-8) to trigger apoptosis [15-17]. When Casp-8 activity is blocked in certain types of cells, RIPK1 recruits RIPK3 to initiate the formation of complex Iib, also known as the necrosome, to initiate necroptosis [18-20]. It is important to point out that unlike its action in mediating the activation of NF-kB and MAP kinases, the pro-necroptotic role of RIPK1 requires its kinase activity and the death receptor-induced necroptosis could be blocked by inhibitors targeting RIPK1 kinase activity [21].

RIPK3 is another member of the RIP kinase family and lacks a death domain [22]. RIPK3 is recruited to the death receptor-induced necrosome by RIPK1 through their RIP Homotypic Interaction Motif (RHIM) interaction and is autophosphorylated in the necrotic complex [18-20]. Subsequently, the activated RIPK3 mediates the recruitment and the phosphorylation of MLKL protein [23, 24]. MLKL is the immediate downstream mediator of RIPK3 in necroptosis and is recruited to the necrosome by RIPK3 [23, 24]. As a pseudo kinase, MLKL contains N-terminal coiled-coil domains and a C-terminal kinase-like domain. After phosphorylation by RIPK3, MLKL oligomerizes through the N-terminal coiled-coil domains and translocates to the plasma membrane [25-28]. It has been suggested that MLKL mediates disruption of plasma membrane permeability by activating ion channels or forming pore structures directly in the plasma membrane [25-28]. Although the key events of necroptosis are believed to happen in the cytosol, interestingly, nuclear translocation of RIPK3 and MLKL has been observed and seems to play a role in accelerating the necrotic process [29, 30].

Although RIPK1 plays an essential role of death receptor-mediated necroptosis, it is not required for viral infection- or Toll-like receptor (TLR)-triggered necroptosis [9]. Z-DNA-binding protein 1 (ZBP1), also known as DNA-dependent activator of interferon (IFN) regulatory factors (DAI), and Toll-interleukin receptor (TIR)-domain-containing adapter-inducing interferon-β (TRIF), two other RHIM domain-containing proteins, have been reported to function upstream of RIPK3-MLKL in viral infection- and TLR-induced necroptosis respectively (Figure 1) [31, 32]. Following viral infection or the ligation of pattern recognition receptors, ZBP1 and TRIF interact with RIPK3 through their RHIM domains to initiate the necrotic process [31, 32]. While RIPK1, ZBP1 and TRIF are involved in different stimuli-induced necroptosis, apparently, there is some cross-talk among these proteins. For instance, it has been found that the necroptosis-inducing activity of ZBP1 is hindered by RIPK1 during normal embryonic development in a RHIM-dependent manner, because deletion of RIPK1 or the disruption of RIPK1 RHIM domain leads to ZBP1-dependent necroptosis and perinatal lethality [33, 34].

**NECROPTOSIS OF TUMOR CELLS AND TUMOR NECROSIs**

Foci of cell death are commonly observed in core regions of solid tumors as a result of inadequate vascularization and subsequent metabolic stresses such as hypoxia and nutrient deprivation [35, 36]. Because the morphology of dead tumor cells appears to be necrotic, these foci of cell death are referred as tumor necrosis [37-39]. Tumor necrosis is often associated with aggressive tumor development and metastasis and is thought to be an indication of
poor prognosis of patients with breast, lung and kidney cancer [38, 39]. However, the exact role of tumor necrosis in tumor development and metastasis remains elusive, because there is no available experimental system to manipulate necrotic cell death in tumors due to the lack of knowledge about the molecular mechanism of necrosis. Even so, some recent studies have started to shed light on the active role of tumor necrosis in tumorigenesis. Unlike apoptosis in which cells have intact membranes and are rapidly removed by host macrophages, it has been shown that tumor necrosis leads to the release of intracellular components to the tumor microenvironment [2, 3]. A recent study found that a high level of potassium was released from necrotic tumor cells [40]. Importantly, this study suggests that the extracellular potassium released from tumor necrosis inhibits both CD4 and CD8 T cell activities that are critical for anti-tumor immunity [40].

To explore the possible molecular mechanism of tumor necrosis, we recently tested if the necroptotic pathway is involved in tumor necrosis. As shown in our publication, we found that MLKL phosphorylation happens in dying cells in tumor necrotic areas and demonstrated that necroptosis is indeed engaged during tumor necrosis [41]. More importantly, tumor necrosis is largely suppressed upon necroptosis blockage by the deletion of MLKL gene and interestingly, the remaining tumor death in MLKL-null tumors is apoptotic [41]. These findings suggest that necroptosis of tumor cells is most likely the major cause of tumor necrosis and provides a feasible tool to assess the role of tumor necrosis in tumorigenesis [41].

Angiogenesis is critical for tumor growth. However, when solid tumors reach a certain size, scant vascularization happens in the core regions of advanced tumors and results in tumor necrosis [35, 36]. In these tumor areas with inadequate vascularization, tumor cells experience metabolic stresses such as hypoxia and nutrient deprivation [35, 36]. Previous studies have shown that metabolic stresses such as hypoxia, glutamine- or glucose-deprivation could trigger apoptotic, autophagy-dependent or necrotic cell death in cancer cells [42, 43]. However, whether these metabolic stress trigger necroptosis in solid tumors is still poorly studied. For example, a recent study suggested that GD (glucose deprivation?) triggers a RIPK1-dependent, non-necroptotic cell death [44]. Therefore, although these metabolic stresses are thought to be responsible for tumor necrosis, it is still not known whether these conditions indeed trigger necroptosis in solid tumors. This knowledge will help to fully understand the mechanism of tumor necrosis and its role in tumorigenesis.
NECROTOPSIS IN TUMORIGENESIS
A dual role in cancer development?
Evasion of programmed cell death is a hallmark of cancer and central to tumor development [10]. As a programmed necrosis, the role of necroptosis in tumor development has been investigated in the last few years. However, because both tumor suppressing and promoting effects have been reported, the role of necroptosis in tumor development is still not fully understood [45]. Several groups reported that RIPK3 expression is inhibited in many tumor cell lines and several types of cancer [46-48]. Restoring RIPK3 expression with the DNA methyl-transferase inhibitor (hypomethylation agent 5-aza-2'-deoxycytidine) potentiates the tumoricidal effects of the chemotherapy drug doxorubicin by inducing necroptosis [46]. More importantly, because necroptotic cell death triggers inflammatory responses, the immune-boosting effect of necroptosis will increase the anti-tumor immunity in the tumor microenvironment [49]. Particularly, the massive acute necroptosis by chemotherapy or irradiation has been shown to elevate anti-tumor immunity [49]. For instance, it has been shown that by releasing pro-inflammatory mediators such as high mobility group box 1 (HMGB1), radiation-induced tumor cell necroptosis may boost anti-tumor immunity and improve prognosis [50]. Interestingly, another report demonstrated that necroptotic cell death triggers robust cross-priming of cytotoxic CD8+ T cells in a RIPK1 and NF-κB-dependent manner, whereas the release of damage-associated molecular patterns (DAMPs) from dead cells alone is not sufficient [51]. This report reveals the critical role of the inflammatory pathway activated in dying cells in promoting anti-tumor immunity [51]. Therefore, these studies suggest that necroptosis may play a tumor suppressor role during tumor development.

Meanwhile, several other studies suggest that necroptosis promotes tumor growth [52, 53]. The study by Seifert et al. reported that necroptosis may have a promoting effect on tumor progression as the key players of necroptosis, RIPK1 and RIPK3, are critical for tumor development [52]. In pancreatic ductal adenocarcinoma (PDA), the necroptotic pathway was found to promote oncogenesis through releasing the chemokine (C-X-C motif) ligand 1 (CXCL1) and 130 kDa Sin3-associated polypeptide (SAP-130), which induce immune-suppression in the tumor microenvironment [52]. In this study, the authors found that CXCL1 is released from PDA cells in a RIPK3-dependent manner and CXCL1 blockage induces tumor regression by reducing the infiltration of immune suppressive MDSCs (myeloid-derived suppressor cells) and M2-like macrophages [52]. Meanwhile, the nucleus factor SAP-130 binds to Macrophage inducible Ca2+-dependent lectin receptor (Mincle), which is expressed on the cell surface of macrophages, and subsequently, those engaged macrophages with Mincle ligation suppress cytotoxic T cell infiltration and activation [52]. Although this study demonstrated the promoting effect of RIPK1 and RIPK3 in tumor development, necroptosis of tumor cells during tumor progression was not investigated. Most recently, we found that necroptosis happens in tumor necrotic areas and that blocking necroptosis switches tumor necrosis to tumor apoptosis [41]. Importantly, as necroptosis only happens in the late stage of tumor development in the breast cancer model used in our study, we found that inhibition of necroptosis reduces the late stage tumor growth and has no effect on tumor initiation and early growth [41]. Interestingly, while consistent with previous findings, we found that RIPK3 expression is decreased in the early stages of mouse MMVT-PyMT breast tumors, a significant increase of RIPK3 expression was detected in late stage tumors that bear tumor necrosis [41]. We also found that MLKL expression was significantly increased as well [41]. These findings suggest that the expression of these key necroptosis mediators is likely reprogrammed to restore the necroptotic machinery in tumor cells when tumors experience metabolic stress. Taken together, the above discussed reports suggested the promoting role of necroptosis in tumor development. The finding that the elevated level of extracellular potassium from tumor necrosis suppresses the anti-tumor immunity supports this notion [40].

It is believed that the anti-tumor function of tumor immunity is mainly achieved by antigen specific, IFN-γ-expressing T cells, whereas the MDSCs, M2-like macrophages and regulatory T cells are the main components of the immune suppressive machinery [53, 54]. It is possible that when massive acute necroptosis happens, for example, following chemotherapy or irradiation treatment, boosting the anti-tumor immunity through activating IFN-γ-expressing T cells will be the dominant effect of necroptosis on tumor immunity (Figure 2). In contrast, when mild chronic necroptosis happens, such as tumor necrosis, the dominant effect of necroptosis on tumor immunity will be immune suppression through consistently releasing immune suppressive molecules to modulate the tumor microenvironment including MDSC and M2-like macrophages (Figure 2). These possibilities are consistent with the conclusion that necroptosis most likely plays a dual role in tumor development. However, further studies are necessary to fully understand the exact role of necroptosis of tumor cells in different stages of tumorigenesis.

A critical facilitator in tumor metastasis?
Metastasis is common in patients with advanced cancer and is the main cause of cancer patient mortality [55, 56]. Although tremendous effort has been made to study metastasis [55], our knowledge about cancer metastasis is still quite limited for developing effective cancer therapies targeting metastasis [56]. Improving our understanding about the mechanism of tumor metastasis will help to identify novel therapeutic targets for containing metastasis. Because alternations of the tumor microenvironment play a critical role in metastasis [55, 56], and, as discussed above, chronic necroptosis has a profound effect on tumor microenvironments, we investigated the effect of blocking necroptosis on metastasis in our recent study [41]. In the orthotopic MVT-1 breast cancer model, we found that
blocking necroptosis of tumor cells by MLKL deletion significantly inhibited lung metastasis [41]. We confirmed that necroptosis inhibits the anti-tumor activity of T cells as reported by earlier studies [40, 52] (unpublished data). Interestingly, the depletion of CD8+ T cells only partially reduced the difference of tumor metastasis between wild tpe and MLKL knock out tumor in the MVT-1 model (unpublished data), indicating that, in addition to inhibiting the anti-tumor activity of T cells, necroptosis likely modulates other aspects of the tumor microenvironment to promote metastasis.

Consistent with this possibility, our study on the regulation of necroptosis showed that a known metastasis promoting factor, soluble E-cadherin (sE-Cadherin), is released from the necrototic cell surface [57]. We found that the cell-surface proteases, A Disintegrin And Metalloproteases (ADAMs), are activated at the very early stage of necroptosis and that all cell-surface proteins including E-cadherin are cleaved by ADAMs [57]. It is known that sE-Cadherin promotes tumor cell invasion and metastasis by interfering with intercellular adhesion junction, increasing matrix metalloproteinases activity, and enhancing angiogenesis [58]. In addition, chemokine CXCL-1 is another necroptosis-activated molecule that is known to promote tumor metastasis [52, 59]. Currently, we are investigating whether those proteins released/increased by necroptosis play a key role in tumor metastasis in spontaneous cancer models in which necroptosis is specifically abolished in tumor cells.

Based on clinical observations, tumor necrosis of solid tumors has long been considered as an indication of metastatic tumors [37-39]. Linking necroptosis of tumor cells with tumor necrosis provides a tool to demonstrate the important role of tumor necrosis in metastasis experimentally and provides a potential novel target for intervening this deadly event of tumorigenesis.

Interestingly, not only necroptosis of tumor cells has the promoting effect on tumor metastasis, necroptosis in other types of cells also plays a key role in advancing metastasis. It is reported that circulating tumor cells induce necroptosis of endothelial cells through engaging death receptor 6 to promote tumor cell extravasation and metastasis [60]. Importantly, the specific inhibitor of RIPK1, necrostatin-1, could efficiently reduce tumor cell extravasation and metastasis [60]. Therefore, targeting necroptosis in general may be an effective novel therapy for restraining metastasis.

**NECROPTOSIS AND TUMORIGENESIS IN PERSPECTIVE**

While recent literature clearly demonstrates the involvement of necroptosis in numerous aspects of tumorigenesis, many fundamental questions regarding the regulation and the role of necroptosis in tumorigenesis remain elusive. Here are a few of examples:

1) what signal(s) triggers necroptosis in tumor cells during tumor development? Do death factors TNF, FasL (Fas ligand) and TRAIL (TNF related apoptosis inducing ligand) play a role in the induction of tumor necroptosis? Although it has been suggested that death receptors-induced necroptosis may play a role in inflammation-driven tumor initiation and development, it has not been demonstrated experimentally that these death factors indeed trigger necroptosis of tumor cells during tumorigenesis.

2) Does the tissue specificity of different types of tumors affect the role of tumor necroptosis in tumorigenesis? So far, the role of necroptosis in tumorigenesis was only tested in limited types of cancers such as PDA and breast cancer [41, 52]. The role of necroptosis in tumorigenesis needs to be examined in other types of solid tumors as well as “liquid tumors” (blood cancers). Interestingly, a recent study suggests that necroptosis plays a key role in liver cancer lineage commitment [61].
3) Is the evasion of necroptosis a critical event for tumor initiation or early development? The findings that RIPK3 expression is silenced in many types of tumor cell lines and cancers and that necroptosis augments the anti-tumor activity of T cells leads to the speculation that necroptosis inhibition may be a key event for tumor development in some types of cancers [46-48, 51]. However, this notion still needs to be evaluated experimentally in cancer models.

4) What are the underlying mechanisms for the promoting effect of tumor necroptosis on tumor development and metastasis in addition to modulation of tumor immunity? Considering the profound effect of tumor necrosis on tumor microenvironments, it is important to investigate what other component(s) of tumor microenvironments in addition to tumor immunity are altered to promote tumor growth and metastasis.

Finally, 5) what is the long-term effect of chemoo/radiation-induced necroptosis on tumor growth and metastasis? The immunogenic effect of acute massive necroptosis is clearly beneficial for chemotherapeutic or radiation-induced initial tumor regression. However, since chronic necroptosis could promote tumor growth and metastasis, will necroptosis by repeated chemotherapeutic or radiation treatments be more anti- or pro-tumorigenesis in the long haul?

Addressing these questions will greatly improve our understanding about the role of necroptosis in tumorigenesis and provide new insights about the possibility and effectiveness of targeting necroptosis as a cancer therapy.

ACKNOWLEDGMENTS
The authors’ research is supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research. We are grateful to Drs. Swati Choksi, Hyung Joon Kwon, Jiong Yan and Zhaoshan Liu for their critical reading of the manuscript.

CONFLICT OF INTEREST
No conflict of interest exists.

COPYRIGHT
© 2019 Liu and Jiao. This is an open-access article released under the terms of the Creative Commons Attribution (CC BY) license, which allows the unrestricted use, distribution, and reproduction in any medium, provided the original author and source are acknowledged.

Please cite this article as: Zheng-gang Liu and Delong Jiao (2019). Necroptosis, tumor necrosis and tumorigenesis. Cell Stress 4(1): 1-8. doi: 10.15698/cst2020.01.208

REFERENCES
1. Kerr JF, Wyllie AH, Currie AR (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26(6): 239-257. doi: 10.1011/j.1365-2796.2005.01570.x
2. Zong WX, Thompson CB (2006). Necrotic death as a cell fate. Genes Dev 20(1): 1-15. doi: 10.1101/gad.1376506
3. Fiers W, Beyaert R, Declercq W, Vandenameele P (1999). More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18(54): 7719-7730. doi: 10.1038/sj.onc.1203249
4. Kroemer G, El-Deiry WS, Golstein P, Peter ME, Vaux DL, Yuan J (2005). Classification of cell death: recommendations of the Nomenclature Committee on Cell Death. Cell Death Differ 12 (Suppl 2): 1463-1467. doi: 10.1038/sj.cdd.4401724
5. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW, et al (2018). Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3): 486-541. doi: 10.1038/s41418-017-0012-4
6. Green DR (2019). The Coming Decade of Cell Death Research: Five Riddles. Cell 177(5): 1094-1107. doi: 10.1016/j.cell.2019.04.024
7. Galluzzi L, Kroemer G (2008). Necroptosis: a specialized pathway of programmed necrosis. Cell 135(7): 1161-1163. doi: 10.1016/j.cell.2008.12.004
8. Christofferson DE, Yuan J (2010). Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 22(2): 263-268. doi: 10.1016/j.cjb.2009.12.016
9. Wallach D, Kang TB, Dillon CP, Green DR (2016). Programmed necrosis in inflammation: Toward identification of the effector molecules. Science 352(6281): aaf2154. doi: 10.1126/science.aaf2154
10. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144(5): 646-674. doi: 10.1016/j.cell.2011.02.013
11. Dixon SJ, Stockwell BR (2019). The Hallmarks of Ferroptosis. Annu Rev Cancer Biol 3(1): 35-54. doi: 10.1146/annurev-cancerbio-030518-055844
12. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, Bodmer JL, Schneider P, Seed B, Tschopp J (2000). Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 1(6): 489-495. doi: 10.1038/33723
13. Ashkenazi A, Dixit VM (1998). Death receptors: signaling and modulation. Science 281(5381): 1305-1308. doi: 10.1126/science.281.5381.1305
14. Guicciardi ME, Gores GJ (2005). Life and death by death receptors. FASEB J 23(6): 1625-1637. doi: 10.1096/fj.08-111005
15. Micheau O, Tschopp J (2003). Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114(2): 181-190. doi: 10.1016/s0092-8674(03)00521-x
16. Wang L, Du F, Wang X (2008). TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133(4): 693-703. doi: 10.1016/j.cell.2008.03.036
17. Xu Q, Jitkaew S, Choksi S, Kadamguwa C, Qu J, Choe M, Jang J, Liu C, Liu ZG (2017). The cytoplasmic nuclear receptor RARgamma controls RIP1 initiated cell death when cIAP activity is inhibited. Nat Commun 8:425. doi: 10.1038/s41467-017-00496-6
18. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK (2009). Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 137 (6): 1112-1123. doi: 10.1016/j.cell.2009.05.037
19. He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X (2009). Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137(6): 1100-1111. doi: 10.1016/j.cell.2009.05.021

20. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong MQ, Han J (2009). RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 325(5938): 332-336. doi: 10.1126/science.1172308

21. Dengtever A, Hitomi J, Germscheid M, Chen’I, Korkina O, Teng X, Abbott D, Curry GD, Yuan C, Wagner G, Hedrick SM, Gerber SA, Lugovskoy A, Yuan J (2008). Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 4(5): 313-321. doi: 10.1038/nchembio.83

22. Sun X, Lee J, Navas T, Baldwin DT, Stewart TA, Dixit VM (1999). RIP3, a novel apoptosis-inducing kinase. J Biol Chem 274(24): 16871-16875. doi: 10.1074/jbc.274.24.16871

23. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, Wang L, Yan J, Liu W, Lei X, Wang X (2012). Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148(1-2): 213-227. doi: 10.1016/j.cell.2011.11.031

24. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, Liu ZG (2012). Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci U S A 109(14): 5322-5327. doi: 10.1073/pnas.120011209

25. Cai Z, Jitkaew S, Zhao J, Chiang HC, Choksi S, Liu J, Ward Y, Wu LG, Liu ZG (2014). Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis. Nat Cell Biol 16(1): 55-65. doi: 10.1038/nclb2883

26. Chen X, Li W, Ren J, Huang D, He WT, Song Y, Yang C, Li W, Zheng X, Chen P, Han J (2014). Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 24(1): 105-121. doi: 10.1038/cr.2013.171

27. Dondelinger Y, Declercq W, Montessuit S, Roelant R, Goncalves M, Dondelinger Y, Declercq W, Martinus JC, Bertrand MJ, Vandenameele P (2014). MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 7(4): 971-981. doi: 10.1016/j.celrep.2014.04.026

28. Wang H, Sun L, Su L, Rizo J, Liu L, Wang LF, Wang FS, Wang X (2014). Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 54(1): 133-146. doi: 10.1016/j.molcel.2014.03.003

29. Yoon S, Bogdanov K, Kovalenko A, Wallach D (2016). Necroptosis is preceded by nuclear translocation of the signaling proteins that induce it. Cell Death Differ 23(2): 253-260. doi: 10.1038/cdd.2015.92

30. Weber K, Roelant R, Bruggeman I, Estornes Y, Vandenameele P (2018). Nuclear RIPK3 and MLKL contribute to cytosolic necroptosis formation and necroptosis. Commun Biol 1(1): 6. doi: 10.1038/s42003-017-0007-1

31. Kaiser WJ, Shridharan H, Huang C, Mandal P, Upton JW, Gough PJ, Sehon CA, Marquiss RW, Bertin J, Mocarski ES (2013). Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 288(43): 31268-31279. doi: 10.1074/jbc.m113.462341

32. Upton JW, Kaiser WJ, Mocarski ES (2012). DAI/ZBP1/DLM-1 complex with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 11(3): 290-297. doi: 10.1016/j.chom.2012.01.016

33. Lin J, Kumari S, Kim C, Van TM, Wachsmuth L, Polykratis A, Pasparakis M (2016). RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation. Nature 540(7631): 124-128. doi: 10.1038/nature20558

34. Newton K, Wickliffe KE, Maltzman A, Dugger DL, Strasser A, Pham VC, Lill JR, Roose-Girma M, Warming S, Solon M, Ngu H, Webster JD, Dixit VM (2016). RIPK1 inhibits ZBP1-driven necroptosis during development. Nature 540(7631): 129-133. doi: 10.1038/nature20559

35. Brown JM, William WR (2004). Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4(6): 437-447. doi: 10.1038/nrc1367

36. Gatenby RA, Gillies RJ (2004). Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4(11): 891-899. doi: 10.1038/nrc1478

37. Makki J (2015). Diversity of Breast Carcinoma: Histological Sub-types and Clinical Relevance. Clin Med Insights Pathol 8: 23-31. doi: 10.4137/cpath.s31563

38. Caruso R, Parisi A, Bonanno A, Paparo D, Quaccurci E, Branca G, Scardigno M, Fedele F (2012). Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief review. Oncol Lett 3(1): 16-18. doi: 10.3892/ol.2011.420

39. Richards CH, Mohammed Z, Qayyum T, Horgan PG, McMillan DC (2011). The prognostic value of histological tumor necrosis in solid organ malignant disease: a systematic review. Future Oncol 7(10): 1223-1225. doi: 10.2217/fon.11.99

40. Eil R1, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Gullattor GC, Yu Z, Car ballo V, Okkenhaug K, Schrumpl DZ, Linehan WM, Roychoudhuri R, Restifo NP (2016). Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537(7621): 539-543. doi: 10.1038/nature19364

41. Jiao D, Cai Z, Choksi S, Ma D, Cho M, Kwon HJ, Bai KY, Rowan BG, Liu C, Zhu GJ (2018). Necroptosis of tumor cells leads to tumor necrosis and promotes tumor metastasis. Cell Res 28(8): 868-870. doi: 10.1038/s41422-018-0058-y

42. Altman BJ, Rathenell JC (2012). Metabolic stress in autoagy and cell death pathways. Cold Spring Harb Perspect Biol 4(9): a008763. doi: 10.1101/cshperspect.a008763

43. Jin S, DiPaola RS, Mathew R, White E (2007). Metabolic catastrophe as a means to cancer cell death. J Cell Sci 120(3): 379-383. doi: 10.1242/jcs.033439

44. Lee HY, Itahana Y, Schuechner S, Fukuda M, Je HS, Ogiris E, Virshup DM, Itahana K (2018). Ca(2+)-dependent demethylation of phosphatase PP2Ac promotes glucose deprivation-induced cell death independently of inhibiting glycolysis. Sci Signal 11(512): eaam7893. doi: 10.1126/scisignal.aam7893

45. Najafov A, Chen H, Yuan J (2017). Necroptosis and Cancer. Trends Cancer 3(4): 294-301. doi: 10.1016/j.trecan.2017.03.002

46. Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, Jordan CT, Yan P, Frank houser D, Nicolet D, Maharry K, Marcucci G, Choi KS, Cho H, Thorburn A, Kim YS (2015). Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res 25(6): 707-725. doi: 10.1038/cr.2015.56

47. Feng X, Song Q, Yu A, Tang H, Peng Z, Wang X (2015). Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer. Neoplasma 62(4): 592-601. doi: 10.4149/neo_2015_071

48. Nuges AL, El Bouazzati H, Hetuin D, Berthon C, Loyens A, Bertrand E, Jouy N, Izdorek T, Quesnel B (2014). RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p53/Rea cleavage. Cell Death Dis 5(8): e1384. doi: 10.1038/cddis.2014.347
49. Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013). Immunogenic cell death in cancer therapy. *Annu Rev Immunol* 31: 51-72. doi: 10.1146/annurev-immunol-032712-100008

50. Wang HH, Wu ZQ, Qian D, Zaorsky NG, Qiu MH, Cheng JJ, Jiang C, Wang J, Zeng XL, Liu CL, Tian LJ, Ying GG, Meng MB, Hao XS, Yuan ZY (2018). Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo. *Int J Radiat Oncol Biol Phys* 101(1): 49-62. doi: 10.1016/j.ijrobp.2018.01.036

51. Yatim N, Jusforgues-Saklani H, Orozco S, Schulz O, Barreira da Silva R, Reis e Sousa C, Green DR, Oberst A, Albert ML (2015). RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. *Science* 350(6258): 328-334. doi: 10.1126/science.aad0395

52. Seifert L, Werba G, Tiwari S, Giao Ly NN, Alqunaibit D, Avanzi A, Barilla R, Daley D, Greco SH, Torres-Hernandez A, Pergamo M, Ochi A, Zambirinis CP, Panosari M, Rendon M, Tippens D, Hundeyin M, Mani VR, Hajdu C, Engle D, Miller G (2016). The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. *Nature* 532(7598): 245-249. doi: 10.1038/nature17403

53. Borst J, Ahrends T, Babala N, Melief CJM, Kastenmuller W (2018). CD4(+) T cell help in cancer immunology and immunotherapy. *Nat Rev Immunol* 18(10): 635-647. doi: 10.1038/s41577-018-0044-0

54. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V (2012). Coordinated regulation of myeloid cells by tumours. *Nat Rev Immunol* 12(4): 253-268. doi: 10.1038/nri3175

55. Lambert AW, Pattabiraman DR, Weinberg RA (2017). Emerging Biological Principles of Metastasis. *Cell* 168(4): 670-691. doi: 10.1016/j.cell.2016.11.037

56. Steeg PS (2016). Targeting metastasis. *Nat Rev Cancer* 16(4): 201-218. doi: 10.1038/nrc.2016.25

57. Cai Z, Zhang A, Choksi S, Li W, Li T, Zhang XM, Liu ZG (2016). Activation of cell-surface proteases promotes necroptosis, inflammation and cell migration. *Cell Res* 26(8): 886-900. doi: 10.1038/cr.2016.87

58. Hu QP, Kuang JY, Yang QK, Bian XW, Yu SC (2016). Beyond a tumor suppressor: Soluble E-cadherin promotes the progression of cancer. *Int J Cancer* 138(12): 2804-2812. doi: 10.1002/ijc.29982

59. Wang D, Sun H, Wei J, Cen B, DuBois RN (2017). CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. *Cancer Res* 77(13): 3655-3665. doi: 10.1158/0008-5472.can-16-3199

60. Strilic B, Yang L, Albarran-Juarez J, Wachsmuth L, Han K, Muller UC, Pasparakis M, Offermanns S (2016). Tumour-cell-induced endothelial cell necrosis promotes death receptor 6 promotes metastasis. *Nature* 536(7615): 215-218. doi: 10.1038/nature19076

61. Seehawer M, Heinzmann F, D’Artista L, Harbig J, Roux PF, Hoenicke L, Dang H, Klotz S, Robinson L, Doré G, Rozenblum N, Kang TW, Chawla R, Buch T, Vucur M, Roth M, Zuber J, Luedde T, Sipos B, Longerich T, Heikenwälder M, Wang XW, Bischof O, Zender L (2018). Necroptosis microenvironment directs lineage commitment in liver cancer. *Nature* 562(7725): 69-75. doi: 10.1038/s41586-018-0519-y